Clinical trial
The Vienna Prograf and Endothelial Progenitor Cell Study
NCT00182559 · Medical University of Vienna, Other · Completed
Key facts
| NCT number | NCT00182559 |
|---|---|
| Title | The Vienna Prograf and Endothelial Progenitor Cell Study |
| Official title | The Vienna Prograf and Endothelial Progenitor Cell Study |
| Lead sponsor | Medical University of Vienna, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | End Stage Renal Disease |
| Intervention type | Drug |
| Interventions | Ciclosporin, Tacrolimus |
| Enrollment | 148 |
| Start date | Apr 1, 2004 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Feb 5, 2014 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: